Commercial Excellence Analyst DACH
About the job
- A completed university degree is required; a degree in Business Administration, Data Analysis, Information Systems, Life Sciences, or a comparable field is preferred.
- At least five years of relevant experience in Sales Force Effectiveness, Sales Planning, Commercial Analytics, CRM, Sales Operations, or Business Excellence is required.
- Experience in a comparable role in the pharmaceutical industry is advantageous.
- Strong analytical skills and the ability to translate market, customer, sales, and activity data into clear commercial insights and recommendations are required.
- Strong communication skills and experience collaborating, coordinating, and influencing cross-functional stakeholders are required.
- A structured and reliable working style, good time and priority management, and the ability to advance multiple topics in parallel are required.
- Flexibility, openness to change, customer orientation, and enjoyment of collaborative teamwork are required.
- Very good knowledge of Excel and PowerPoint is required; experience with Access, CRM, Veeva, Salesforce, or business intelligence tools is advantageous.
- Fluent German and English are required.
- Develop meaningful market, customer, and competitor analyses and use regular reviews to further develop commercial strategies with the teams.
- Define relevant KPIs, ensure reliable performance tracking, and translate data into clear recommendations for sales, management, and partner functions.
- Steer Sales Force Effectiveness initiatives such as segmentation, targeting, visit planning, and territory structures, and ensure their practical use within teams.
- Own accurate and timely sales reporting and prepare analyses as needed on revenue, activities, performance, portfolio, and team productivity.
- Coordinate central Sales Operations processes, including bonus planning, the quarterly Sales Incentive Plan, and Multichannel Call Planning processes for Germany.
- Ensure high quality of customer and healthcare professional master data, develop CRM processes, and support Sales Managers and new Product Specialists in using systems correctly.
- Support Digital, Key Account Management, and other cross-functional teams with recurring and ad hoc analysis needs, making complex data useful for informed decisions.
- Drive initiatives with DACH Sales Managers and the Management Team to increase revenue, productivity, and operational efficiency, and use Business Excellence tools effectively.
- Experience in a comparable role in the pharmaceutical industry.
- Experience with Access, CRM, Veeva, Salesforce, or business intelligence tools.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
- EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
- JUVMO launches in October 2026, adding a fresh neuroscience revenue line.
What critics are saying
- Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
- Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
- Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
- JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
- AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%AbbVie and Medtronic are positioned as attractive dividend stock investments despite market volatility, according to a recent analysis. AbbVie, a Dividend King with 53 consecutive years of dividend increases, offers a 2.6% forward yield and trades at 16 times next year's earnings. The pharmaceutical company has successfully offset its Humira patent loss through strategic acquisitions and new blockbuster drugs like Skyrizi and Rinvoq. Analysts expect revenue and adjusted earnings per share to grow at compound annual growth rates of 9% and 21%, respectively, from 2025 to 2028. Medtronic, approaching Dividend King status with 49 consecutive years of dividend hikes, provides a 3.3% forward yield. The medical device maker's turnaround efforts, including spinning off its diabetes unit and focusing on cardiovascular and neuroscience businesses, have driven organic revenue growth to 5.8%. Trading at 18 times this year's earnings, both stocks appear undervalued relative to their growth prospects.
Top biotech stocks to add to your watchlist - october 3rd. October 3, 2026 Key points. * Moderna, AbbVie, and Amgen are highlighted as biotech stocks to watch based on their recent high dollar trading volume. * Moderna develops messenger RNA vaccines and therapeutics across areas including respiratory, infectious, autoimmune, cardiovascular, and cancer-related diseases. * AbbVie and Amgen offer broad pharmaceutical portfolios spanning immunology, oncology, osteoporosis, cardiovascular care, and other chronic conditions; biotech investments can provide substantial growth but carry risks tied to trials, regulatory approvals, patents, and funding. * MarketBeat previews the top five stocks to own by November 1st. Moderna, AbbVie, and Amgen are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop products or technologies based on biology, such as medicines, vaccines, diagnostics, and gene therapies. For investors, these stocks can offer significant growth potential but often carry high risks because their value may depend on clinical-trial results, regulatory approvals, intellectual property, and the companies' ability to secure funding. These companies had the highest dollar trading volume of any Biotech stocks within the last several days. Moderna (MRNA). Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. AbbVie (ABBV). AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Amgen (AMGN). Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Moderna, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list. While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public. Continue following MarketBeat
About adarx Pharmaceuticals. ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. BiopharmaWatch has developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to its wholly-owned programs, BiopharmaWatch has entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.
Migraine annual economic and quality-of-life burden in UK. Migraine affects an estimated 280,000 people across Greater Manchester and creates an annual economic and quality-of-life burden of around £870m, according to a report from Health Innovation Manchester and AbbVie UK. The report, based on linked healthcare data, health economic modelling, pathway analysis and patient and healthcare professional insights, estimates that £546m of the burden relates to quality-of-life impacts, £295m to lost productivity and £29m to direct healthcare costs. It found that only around one-third of people thought to have migraine are captured in recorded diagnosed or actively treated populations, although gaps in diagnosis and routine recording mean the true burden may be higher. The analysis also identified variation in diagnosis, treatment and access to specialist care. Of patients newly diagnosed between 2019 and 2024, 55% received preventative treatment, while around 1% reached fourth-line treatment during the evaluation period. The report recommends a standardised NICE-aligned migraine pathway, greater capacity in primary and community care, a population health approach to identifying unmet need, and more consistent treatment review and escalation. Laura Rooney, Deputy Chief Executive at Health Innovation Manchester, said: "Many people are living without a diagnosis, navigating fragmented services or waiting too long for their treatment to be reviewed and optimised." The report was produced through a collaborative working project between Health Innovation Manchester and AbbVie. It concludes that the findings could inform migraine care planning elsewhere in the UK, although the analysis is specifically based on Greater Manchester.
Abbott Laboratories has launched SimpleScreen CRC in the US, an FDA-approved blood-based colorectal cancer screening test for average-risk adults who decline traditional screening methods. The company's share price has fallen 10.2% over one month, though it remains up 9.5% over 90 days. The one-year total shareholder return stands at negative 22.9%, suggesting investors are reassessing growth potential around the current $100.95 share price. The most followed valuation narrative points to a fair value of $120.26, implying the stock is 16% undervalued. This valuation factors in the scaling of Abbott's cancer diagnostics portfolio and expected contributions of approximately $3 billion in 2026 sales. However, the company faces pressure from ongoing nutrition legal settlements and higher expansion spending for its Libre product line.